Jubilant Hollisterstier's pharmaceutical sterile manufacturing facility in Spokane, Washington (USA) has been upgraded to the status of Voluntary Action Indicated (VAI) by the US Food and Drug Administration (USFDA).
The Spokane site’s latest Establishment Inspection Report (EIR) indicates the inspections in April 2014 and December 2014 have been successfully concluded. This upgradation by the USFDA from Official Action Indicated (OAI) to VAI is indicative of the cGMP status at the facility since receiving the warning letter in 2013.
Commenting on the above development, Shyam S Bhartia, chairman and Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences, say “Jubilant remains committed to continuous improvements to maintain compliance at all its pharmaceutical manufacturing facilities across the globe. We consider this development as another step towards building a reliable and sustainable pharmaceutical business”.
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, generics, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery. The company’s strength lies in its unique offerings of pharmaceutical and life sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of about 6,200 multicultural people across the globe, the company is committed to deliver value to its customers spread across over 100 countries. The company is well recognized as a ‘partner of choice’ by leading pharmaceuticals and life sciences companies globally.